Fasifree 10% w/v Oral Suspension

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Triclabendazole

제공처:

Cross Vetpharm Group Limited

ATC 코드:

QP52AC01

INN (International Name):

Triclabendazole

복용량:

10 percent weight/volume

약제 형태:

Oral suspension

처방전 유형:

LM: Licensed Merchant as defined in relevant national legislation

치료 그룹:

Cattle, Sheep

치료 영역:

triclabendazole

치료 징후:

Endoparasiticide

승인 상태:

Authorised

승인 날짜:

2002-02-22

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fasifree 10% w/v Oral Suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension.
A white to off-white oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of adult, immature and early immature
stages of liver fluke (_Fasciola hepatica)_ susceptible to
triclabendazole.
4.3 CONTRAINDICATIONS
Do not use in animals known to be hypersensitive to the active
substance.
Each ml contains:
ACTIVE SUBSTANCE
Triclabendazole
100 mg
EXCIPIENTS
Methyl Parahydroxybenzoate (E218) Ph.Eur.
2.0 mg (preservative)
Propyl Parahydroxybenzoate (E216) Ph.Eur.
0.2 mg (preservative)
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_5_
_9_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and could
ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
Underdosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of
calibration of the dosing device.
Suspected clinical cases of re